An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

Joseph J Gingell, John Simms, James Barwell, David Poyner, Harriet A Watkins, Augen A Pioszak, Patrick M Sexton, Debbie Hay

Research output: Contribution to journalArticleResearchpeer-review

Abstract

G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein-protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.

Original languageEnglish
Article number16012
Number of pages14
JournalCell Discovery
Volume2
DOIs
Publication statusPublished - 17 May 2016

Keywords

  • Amylin
  • accessory protein
  • CGRP
  • G protein-coupled receptor
  • RAMP

Cite this

Gingell, J. J., Simms, J., Barwell, J., Poyner, D., Watkins, H. A., Pioszak, A. A., ... Hay, D. (2016). An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discovery, 2, [16012]. https://doi.org/10.1038/celldisc.2016.12
Gingell, Joseph J ; Simms, John ; Barwell, James ; Poyner, David ; Watkins, Harriet A ; Pioszak, Augen A ; Sexton, Patrick M ; Hay, Debbie. / An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. In: Cell Discovery. 2016 ; Vol. 2.
@article{d8b42a3b4bba4acf8b9e4f47083d716b,
title = "An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology",
abstract = "G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein-protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.",
keywords = "Amylin, accessory protein, CGRP, G protein-coupled receptor, RAMP",
author = "Gingell, {Joseph J} and John Simms and James Barwell and David Poyner and Watkins, {Harriet A} and Pioszak, {Augen A} and Sexton, {Patrick M} and Debbie Hay",
year = "2016",
month = "5",
day = "17",
doi = "10.1038/celldisc.2016.12",
language = "English",
volume = "2",
journal = "Cell Discovery",
issn = "2056-5968",
publisher = "Springer Nature [academic journals on nature.com]",

}

Gingell, JJ, Simms, J, Barwell, J, Poyner, D, Watkins, HA, Pioszak, AA, Sexton, PM & Hay, D 2016, 'An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology' Cell Discovery, vol. 2, 16012. https://doi.org/10.1038/celldisc.2016.12

An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. / Gingell, Joseph J; Simms, John; Barwell, James; Poyner, David; Watkins, Harriet A; Pioszak, Augen A; Sexton, Patrick M; Hay, Debbie.

In: Cell Discovery, Vol. 2, 16012, 17.05.2016.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

AU - Gingell, Joseph J

AU - Simms, John

AU - Barwell, James

AU - Poyner, David

AU - Watkins, Harriet A

AU - Pioszak, Augen A

AU - Sexton, Patrick M

AU - Hay, Debbie

PY - 2016/5/17

Y1 - 2016/5/17

N2 - G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein-protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.

AB - G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes, G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins (RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled receptors. Prototypic is the calcitonin receptor, with altered ligand specificity when co-expressed with RAMPs. To gain molecular insight into the consequences of this protein-protein interaction, we combined molecular modelling with mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allosterically influence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the calcitonin receptor extracellular N-terminal domain is more flexible in the presence of receptor activity-modifying protein 1. Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states, explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.

KW - Amylin

KW - accessory protein

KW - CGRP

KW - G protein-coupled receptor

KW - RAMP

UR - http://www.scopus.com/inward/record.url?scp=85018030657&partnerID=8YFLogxK

U2 - 10.1038/celldisc.2016.12

DO - 10.1038/celldisc.2016.12

M3 - Article

VL - 2

JO - Cell Discovery

JF - Cell Discovery

SN - 2056-5968

M1 - 16012

ER -

Gingell JJ, Simms J, Barwell J, Poyner D, Watkins HA, Pioszak AA et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discovery. 2016 May 17;2. 16012. https://doi.org/10.1038/celldisc.2016.12